Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. develops targeted oncology therapies for patients with RAS-addicted cancers. Company news centers on its RAS(ON) inhibitor pipeline, including daraxonrasib, a RAS(ON) multi-selective inhibitor, and selective programs such as elironrasib, zoldonrasib and RMC-5127.
Recurring updates cover clinical data in pancreatic ductal adenocarcinoma, non-small cell lung cancer and other RAS-mutant solid tumors, presentations at oncology meetings, scientific publications, regulatory interactions and trial-stage progress. Revolution Medicines also reports quarterly financial results, financing activity and corporate progress tied to research and development, potential commercialization planning and its broader RAS(ON) discovery platform.
Revolution Medicines (NASDAQ: RVMD) announced that the New England Journal of Medicine published Phase 1/2 data for daraxonrasib in previously treated metastatic RAS‑mutant pancreatic ductal adenocarcinoma (PDAC). The published results supported initiation of the global Phase 3 registrational trial RASolute 302.
According to the company, Phase 1/2 data showed clinical antitumor activity, durable responses, and an acceptable safety profile; the company also announced positive topline RASolute 302 results reporting an overall survival benefit versus standard cytotoxic chemotherapy.
Revolution Medicines (Nasdaq: RVMD) reported Q1 2026 results and clinical progress on May 6, 2026. Key highlights: daraxonrasib showed a median overall survival of 13.2 months vs 6.7 months (HR 0.40; p<0.0001) in Phase 3 RASolute 302 for previously treated PDAC, with plans to submit to global regulators and present at ASCO.
The company closed concurrent financings raising $2.225 billion gross, holds $1.9 billion cash (Mar 31) and received approximately $2.1 billion net in April; updated 2026 GAAP operating expense guidance is $1.7–$1.8 billion.
Revolution Medicines (Nasdaq: RVMD) will report first-quarter 2026 financial results on May 6, 2026 after market close. A live webcast with senior management will begin at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and corporate progress.
The live webcast and an archived replay (available for at least 14 days) can be accessed via the company's investor events and presentations page.
Revolution Medicines (Nasdaq: RVMD) will present updated Phase 1/2 data for daraxonrasib in first-line metastatic pancreatic ductal adenocarcinoma at AACR 2026.
As of Dec 1, 2025, daraxonrasib plus gemcitabine/nab-paclitaxel (n=40) showed a confirmed ORR 58% and 6-month PFS estimate 84%. Daraxonrasib monotherapy (n=40) showed ORR 47% and 6-month PFS 71%. Safety was described as manageable; median PFS and OS were not mature. The company says these data support ongoing Phase 3 evaluation, and the company recently reported RASolute 302 met primary and key secondary endpoints including PFS and OS.
Revolution Medicines (Nasdaq: RVMD) will present preclinical data for RM-055 at the AACR Annual Meeting on April 21, 2026, showing a novel catalytic RAS(ON) mechanism that accelerates hydrolysis of mutant RAS-GTP to RAS-GDP.
In preclinical models, RM-055 drove deep, durable regressions across KRAS G12 pancreatic, NSCLC, and colorectal xenografts, including tumors that had escaped prior RAS inhibitors, and preferentially suppressed mutant tumors versus normal tissues.
Revolution Medicines (NASDAQ: RVMD) will present detailed Phase 3 RASolute 302 results for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC) at the 2026 ASCO Annual Meeting.
The company reported topline results showing daraxonrasib met all primary and key secondary endpoints, with statistically significant improvement in progression-free survival and overall survival versus standard chemotherapy. The plenary presentation is May 31, 2026 at 3:21 PM CDT in McCormick Place, Hall B1.
Revolution Medicines (Nasdaq: RVMD) presented updated Phase 1 (RMC-9805-001) data for zoldonrasib, a KRAS G12D-selective oral inhibitor, at AACR 2026 on April 19, 2026. Data (cutoff Dec 1, 2025) included 40 safety-evaluable NSCLC patients at 1,200 mg daily and an efficacy subset (n=27) with prior checkpoint inhibitor and platinum chemotherapy.
Key results: confirmed objective response rate 52%, disease control rate 93%, median PFS 11.1 months, median duration of response not yet estimable, and manageable safety with Grade 3 TRAEs in 13%.
Revolution Medicines (Nasdaq: RVMD) closed concurrent upsized public offerings on April 17, 2026, raising approximately $2,225.0 million gross and an estimated $2,137.2 million net. The transactions included 12,147,887 common shares at $142.00 per share and $500.0 million of 0.50% convertible senior notes due 2033.
The notes carry a 0.50% coupon, an initial conversion rate of 5.0302 shares per $1,000 principal (≈$198.80 per share), and various conversion, redemption and repurchase provisions. Proceeds are for general corporate purposes, including R&D and potential commercialization expenses.
Revolution Medicines (NASDAQ:RVMD) priced concurrent offerings raising approximately $2.0 billion in aggregate: 10,563,381 shares of common stock at $142.00 per share (~$1.5 billion gross) and $500.0 million aggregate principal of 0.50% convertible senior notes due 2033.
Common settlement is scheduled April 16, 2026 and note settlement April 17, 2026. Net proceeds are estimated at ~$1,435.0 million from the common offering and ~$486.8 million from the note offering, for general corporate purposes.
Revolution Medicines (NASDAQ:RVMD) announced proposed public offerings of $750 million of common stock and $250 million aggregate principal amount of convertible senior notes due 2033, with underwriter overallotment options of $112.5 million and $37.5 million, respectively.
The notes will be senior unsecured, accrue interest semi-annually, be convertible under specified circumstances, and may be redeemable after May 6, 2030. Net proceeds are for general corporate purposes including R&D and commercialization expenses.